Trial Profile
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary)
- Indications Adenocarcinoma; Malignant melanoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Bio-Cancer Treatment International
- 12 Jul 2021 Results determining the safety, pharmacokinetics/pharmacodynamics (PK/PD), and recommended Phase II dosage published in the Investigational New Drugs
- 22 Apr 2020 Status changed from recruiting to completed.
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.